Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating

Baxter International (NYSE:BAX) is one of the 10 Best Medical Stocks to Buy Under $30. On April 6, Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Baxter International (NYSE:BAX) from $23 to $22 while maintaining an Outperform rating on the stock. This comes as part of the firm’s first-quarter preview of the medical technology and life science tools sector.

Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating

Earlier, on March 30, Baxter International Inc. (NYSE:BAX) introduced the IV Verify Line Labeling System at the 2026 American Organization for Nursing Leadership Conference. This system is an automated solution that is designed to streamline nursing workflows, support safer medication administration at the bedside, and save clinician time. This launch by Baxter International Inc. (NYSE:BAX) comes after a strategic and exclusive distribution agreement with Vigilant Software, which specializes in medication management safe practices.

Clinicians will be able to use the IV Verify system to scan a medication barcode to instantly print a three-part adhesive label. The label will include the drug name, administration time, and tubing change times, which can then be placed on the tubing. This provides a clear and simple solution that supports labeling compliance and patient safety.

Baxter International (NYSE:BAX) is a medical technology company and an innovative leader in infusion therapies and platforms. It is known for its portfolio of connected solutions, medical devices, and advanced injectable technologies.

While we acknowledge the risk and potential of BAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BAX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Fintech Stocks to Invest In According to Billionaires and 10 Unrivaled Stocks of the Next 5 Years.

Disclosure: None.  Follow Insider Monkey on Google News.